Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function
- PMID: 20351194
- DOI: 10.4049/jimmunol.1000173
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function
Abstract
Protective adaptive immune responses rely on TCR-mediated recognition of Ag-derived peptides presented by self-MHC molecules. However, self-Ag (tumor)-specific TCRs are often of too low affinity to achieve best functionality. To precisely assess the relationship between TCR-peptide-MHC binding parameters and T cell function, we tested a panel of sequence-optimized HLA-A(*)0201/NY-ESO-1(157-165)-specific TCR variants with affinities lying within physiological boundaries to preserve antigenic specificity and avoid cross-reactivity, as well as two outliers (i.e., a very high- and a low-affinity TCR). Primary human CD8 T cells transduced with these TCRs demonstrated robust correlations between binding measurements of TCR affinity and avidity and the biological response of the T cells, such as TCR cell-surface clustering, intracellular signaling, proliferation, and target cell lysis. Strikingly, above a defined TCR-peptide-MHC affinity threshold (K(D) < approximately 5 muM), T cell function could not be further enhanced, revealing a plateau of maximal T cell function, compatible with the notion that multiple TCRs with slightly different affinities participate equally (codominantly) in immune responses. We propose that rational design of improved self-specific TCRs may not need to be optimized beyond a given affinity threshold to achieve both optimal T cell function and avoidance of the unpredictable risk of cross-reactivity.
Similar articles
-
Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.Immunol Lett. 2009 Aug 15;125(2):86-92. doi: 10.1016/j.imlet.2009.06.002. Epub 2009 Jun 12. Immunol Lett. 2009. PMID: 19524620
-
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.J Immunol. 2009 Oct 15;183(8):5397-406. doi: 10.4049/jimmunol.0901460. Epub 2009 Sep 28. J Immunol. 2009. PMID: 19786555 Clinical Trial.
-
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15010-5. doi: 10.1073/pnas.0807954105. Epub 2008 Sep 22. Proc Natl Acad Sci U S A. 2008. PMID: 18809922 Free PMC article.
-
[MHC tetramers: tracking specific immunity].Acta Med Croatica. 2003;57(4):255-9. Acta Med Croatica. 2003. PMID: 14639858 Review. Croatian.
-
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.Curr Opin Immunol. 2015 Apr;33:16-22. doi: 10.1016/j.coi.2015.01.003. Epub 2015 Jan 22. Curr Opin Immunol. 2015. PMID: 25618219 Free PMC article. Review.
Cited by
-
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation.Mol Ther. 2020 Dec 2;28(12):2564-2576. doi: 10.1016/j.ymthe.2020.08.003. Epub 2020 Aug 8. Mol Ther. 2020. PMID: 32827460 Free PMC article.
-
Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.Angew Chem Int Ed Engl. 2015 Jun 8;54(24):7022-7. doi: 10.1002/anie.201500799. Epub 2015 Apr 27. Angew Chem Int Ed Engl. 2015. PMID: 25919418 Free PMC article.
-
Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.Cancer Immunol Res. 2013 Aug;1(2):99-111. doi: 10.1158/2326-6066.CIR-13-0047. Cancer Immunol Res. 2013. PMID: 24459675 Free PMC article.
-
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.Cancer Immunol Immunother. 2011 Nov;60(11):1553-64. doi: 10.1007/s00262-011-1061-z. Epub 2011 Jun 17. Cancer Immunol Immunother. 2011. PMID: 21681371 Free PMC article. Clinical Trial.
-
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.Mol Ther Oncolytics. 2017 Jan 11;3:1-9. doi: 10.1038/mto.2016.23. eCollection 2016. Mol Ther Oncolytics. 2017. PMID: 29675462 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials